Company Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.
It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps.
The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.
Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| IPO Date | May 1, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Dr. Maria Palasis Ph.D. |
Contact Details
Address: 480 Arsenal Way Watertown, Massachusetts United States | |
| Website | https://lyratherapeutics.com |
Stock Details
| Ticker Symbol | LYRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001327273 |
| CUSIP Number | 55234L105 |
| ISIN Number | US55234L1052 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria Palasis Ph.D. | Chief Executive Officer, President & Director |
| Jason Cavalier | Chief Financial Officer, Treasurer & Secretary |
| Ronan P. O'Brien J.D. | Chief Legal Officer |
| Dr. Carmichael S. Roberts Jr., Ph.D. | Co-Founder |
| Dr. Harlan W. Waksal M.D. | Executive Chairman |
| Dr. Robert Kern M.D. | Chief Clinical Advisor |
| Dr. Robert Richard Ph.D. | Senior Vice President of Technical Operations |
| Gloria Cosgrove | Senior Vice President of Quality |
| Ray Knox | Vice President of Operations |
| Vineeta Belanger Ph.D. | Senior Vice President of Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 4 | Filing |
| Dec 11, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 18, 2024 | 4 | Filing |